Efficacy and safety of immunosuppressive therapy in myelin oligodendrocyte glycoprotein antibody–associated disease: a systematic review and meta-analysis
Background: A considerable number of patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) will experience a relapse, but the effect of maintenance therapies on re-attack rates is currently unknown. Objective: To investigate the efficacy and safety of immunosuppressiv...
Guardado en:
Autores principales: | Qi-Lun Lai, Yin-Xi Zhang, Meng-Ting Cai, Yang Zheng, Song Qiao, Gao-Li Fang, Chun-Hong Shen |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
SAGE Publishing
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4673307f7a234bfa90ef9addc29e47c1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes
por: Marta Simone, et al.
Publicado: (2021) -
Replenishing the Aged Brains: Targeting Oligodendrocytes and Myelination?
por: Xi Zhang, et al.
Publicado: (2021) -
A morphological analysis of activity-dependent myelination and myelin injury in transitional oligodendrocytes
por: Eszter Toth, et al.
Publicado: (2021) -
Evolutionary Origins of the Oligodendrocyte Cell Type and Adaptive Myelination
por: Jacob H. Hines
Publicado: (2021) -
MRI Prognostic Factors in Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Antibody Disease
por: Rosa Cortese, et al.
Publicado: (2021)